The company's goal, Strive Health CEO Riopelle told Insider at the time of the Series B, is to slow the progression of the disease and ultimately help them avoid the need for dialysis in clinics like the onesoperate. Dialysis treatment cleans the blood for patients whose kidneys don't function well enough to provide that function on their own.
Riopelle said few companies collect and interpret data on patients with kidney disease, who are typically complex and expensive to care for. Strive uses that data to make predictions about what a patient's progress may be, what type of clinician is best suited to working with them, and how likely they are to progress in the disease quickly.80,000 patients with chronic or end-stage kidney disease in 30 states, according to the company.